Shifting gears with CAR T cells for autoimmune diseases

Just a few weeks ago at the American Society of Hematology Annual Meeting, Mueller et al. presented remarkable data from their ongoing study testing CD19-directed chimeric antigen receptor (CAR) T cell therapy for autoreactive B cell diseases including systemic lupus erythematosus (SLE), idiopathic inflammatory myositis (IIM), and systemic sclerosis (SSc).1